{"gene":"MLANA","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":1994,"finding":"The MART-1 protein contains an immunodominant HLA-A2-restricted CTL epitope corresponding to the 9-mer peptide AAGIGILTV (residues 27-35), which is recognized by the majority of HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes.","method":"Peptide synthesis based on HLA-A2.1 binding motifs, T2 cell pulsing, cytolysis assays with TIL from 10 patients","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct peptide-MHC binding and functional CTL lysis assay, replicated across 10 patients and subsequently confirmed by mass spectrometry (PMID:10417764) and multiple independent labs","pmids":["7516411"],"is_preprint":false},{"year":1997,"finding":"The decapeptide EAAGIGILTV (residues 26-35) is the optimal-length immunodominant MART-1 peptide for HLA-A*0201 presentation; it binds HLA-A2 more efficiently than the nonapeptide AAGIGILTV (residues 27-35) and is recognized at lower concentrations by the majority of Melan-A-specific CTL clones.","method":"Quantitative functional CTL assays (4 polyclonal and 13 monoclonal CTL populations), peptide-HLA-A2 binding assays, TCR repertoire analysis","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct binding assays combined with functional CTL recognition, multiple clones tested, findings consistent with independent replication","pmids":["9278327"],"is_preprint":false},{"year":1996,"finding":"MART-1 protein is approximately 20-22 kDa (detected as a doublet by SDS-PAGE) and localizes to the cytoplasm of melanocytes and melanoma cells; subcellular fractionation placed MART-1 in melanosomes and endoplasmic reticulum, and no known melanogenic enzymatic activities were detected in MART-1.","method":"Recombinant protein production, monoclonal antibody generation, immunoprecipitation, Western blotting, immunocytochemistry, subcellular fractionation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal biochemical methods (western, IP, fractionation, ICC) in a single study; subcellular localization confirmed but functional consequence of fractionation result not fully established","pmids":["8650193"],"is_preprint":false},{"year":1997,"finding":"MART-1 protein size is approximately 18 kDa by SDS-PAGE, suggesting possible post-translational modifications; the protein localizes to melanosomes and endoplasmic reticulum by subcellular fractionation, and no melanogenic enzymatic activities were detected.","method":"Bacterial and baculovirus recombinant expression, immunoprecipitation, Western blotting, flow cytometry, subcellular fractionation","journal":"Journal of immunological methods","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods in a single study; fractionation supports ER/melanosome localization but functional consequence not established","pmids":["9075767"],"is_preprint":false},{"year":2002,"finding":"Melan-A/MART-1 is post-translationally acylated and undergoes rapid turnover; its highest concentration is in the trans-Golgi network and small vesicles/tubules throughout the cell, with substantial labeling also on melanosomes (concentrated on the limiting membrane of premelanosomes, shifting to internal vesicle membranes upon melanosome maturation), endosomes, ER, nuclear envelope, and plasma membrane — a subcellular distribution distinct from typical melanosomal proteins, suggesting a role in early melanosome biogenesis.","method":"Biochemical acylation analysis, immunofluorescence microscopy, quantitative immunoelectron microscopy","journal":"Traffic (Copenhagen, Denmark)","confidence":"High","confidence_rationale":"Tier 1 / Strong — quantitative immunoelectron microscopy with biochemical acylation data; multiple orthogonal methods in a single study; subcellular distribution precisely mapped","pmids":["12191019"],"is_preprint":false},{"year":2005,"finding":"MART-1 forms a physical complex with Pmel17/GP100 and is required for Pmel17's expression, stability, trafficking, and proteolytic processing necessary for melanosome structure and maturation; siRNA-mediated knockdown of MART-1 in pigmented cells impairs Pmel17 function, and re-expression of MART-1 in MART-1-negative cells rescues Pmel17 processing.","method":"siRNA knockdown, transfection rescue, co-immunoprecipitation, Western blotting, electron microscopy of melanosome ultrastructure","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — co-IP demonstrates physical complex; siRNA loss-of-function and rescue experiments with defined molecular readout (Pmel17 processing/stability); multiple orthogonal methods in one study","pmids":["15695812"],"is_preprint":false},{"year":2009,"finding":"MART-1 interacts biochemically with the intracellular GPCR OA1 (GPR143); siRNA inactivation of MART-1 leads to decreased OA1 stability and similar defects in premelanosome biogenesis and composition as OA1 loss, suggesting MART-1 acts as an escort protein for OA1 at early stages of melanogenesis.","method":"siRNA knockdown of MART-1 and OA1, co-immunoprecipitation, immunofluorescence, electron microscopy of melanosome ultrastructure","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — co-IP establishes physical interaction; siRNA loss-of-function with defined ultrastructural and biochemical phenotype; multiple orthogonal methods","pmids":["19717472"],"is_preprint":false},{"year":2003,"finding":"MLANA/MART-1 gene expression is transcriptionally regulated by the MITF transcription factor; the MLANA promoter/enhancer contains conserved MITF consensus DNA-binding sequences that are bound by MITF in vitro and in vivo, and modulation of MITF levels correspondingly changes endogenous MLANA expression in melanoma cells.","method":"Electrophoretic mobility shift assay (EMSA), chromatin immunoprecipitation (ChIP), promoter/reporter assays, MITF up/down-regulation in melanoma cell lines","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 1 / Strong — EMSA and ChIP both demonstrate MITF binding to MLANA regulatory sequences; reporter assays confirm functional transcriptional regulation; multiple orthogonal methods in one study","pmids":["12819038"],"is_preprint":false},{"year":2011,"finding":"MART-1 knockdown mice display coat color dilution with reduced total melanin content; MART-1 loss causes morphological abnormalities specifically in stage III and IV melanosomes of hair follicle melanocytes but does not affect localization of other melanocyte-specific proteins or maturation of Pmel17, indicating MART-1 is required for late-stage melanosome biogenesis and/or maintenance.","method":"MART-1 knockout mouse model, coat color phenotyping, electron microscopy of melanosomes, immunofluorescence for melanocyte-specific proteins","journal":"Pigment cell & melanoma research","confidence":"High","confidence_rationale":"Tier 1 / Strong — germline knockout with defined melanin content and ultrastructural phenotype; multiple orthogonal methods; provides in vivo validation of melanosomal function","pmids":["21943097"],"is_preprint":false},{"year":1999,"finding":"MART-1 peptide AAGIGILTV (residues 27-35) is directly identified by mass spectrometry as a naturally processed and HLA-A*0201-associated peptide isolated from the surface of human melanoma cells, confirming the endogenous processing and presentation of this CTL epitope.","method":"Peptide isolation from HLA-A*0201 molecules of melanoma cells followed by mass spectrometry identification","journal":"International journal of cancer","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct mass-spectrometric identification of naturally processed peptide from tumor cell HLA molecules; rigorous biochemical method confirming endogenous processing","pmids":["10417764"],"is_preprint":false},{"year":2000,"finding":"MART-1 encodes at least one HLA-DR4-restricted epitope (residues 51-73) recognized by CD4+ T cells; Melan-A/MART-1(51-73)-specific CD4+ T cells specifically produce IFN-γ and lyse T2.DR4 cells pulsed with the peptide and DR4+ melanoma cells naturally expressing MART-1.","method":"In vitro expansion of CD4+ T cells with peptide-pulsed autologous dendritic cells, cytokine production assay (IFN-γ), cytolysis assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional T cell recognition assay with defined peptide epitope and HLA restriction; single lab but two orthogonal functional readouts (cytokine and cytolysis)","pmids":["10618430"],"is_preprint":false},{"year":2001,"finding":"Melanoma cells secrete a soluble protein factor that down-regulates MART-1/Melan-A antigen expression by acting on the MART-1 minimal promoter, leading to loss of CTL recognition; this silencing is reversible upon removal of conditioned supernatants and does not affect the HLA-A2 promoter.","method":"Promoter activity assays, conditioned media experiments, CTL recognition assay, reversal upon supernatant removal","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter assays with conditioned media plus functional CTL readout; single lab, two orthogonal methods; identity of soluble factor not determined","pmids":["11466335"],"is_preprint":false},{"year":1995,"finding":"TCR alpha chain variable region TCRAV2S1 was the predominant chain in MART-1-specific HLA-A2-restricted CTL clones (6/9 clones from 5 patients), with restricted beta-chain usage (TCRBV14 or TCRBV7), and a conserved TCRAV2S1/TCRBV14 pairing in 4 clones from 3 patients, indicating limited and conserved TCR gene usage in the anti-MART-1 CTL response.","method":"PCR with V-region gene subfamily-specific primers on cDNA from CTL clones, DNA sequencing","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct TCR sequencing from multiple patient-derived clones; single study but across 5 patients with consistent findings","pmids":["7777568"],"is_preprint":false},{"year":1996,"finding":"MART-1 peptide AAGIGILTV (27-35) is presented not only by HLA-A*0201 but also by at least six HLA-A2 variants (A*0202, A*0204, A*0205, A*0206, A*0209, and A*6901), as demonstrated by sensitization of B-LCLs expressing these alleles to lysis by MART-1(27-35)-specific CTL.","method":"Peptide pulsing of B-LCLs expressing defined HLA-A2 subtypes, cytolysis assays with MART-1-specific CTL, peptide-binding studies","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional peptide-MHC presentation demonstrated across multiple alleles; single lab but comprehensive allele panel","pmids":["8752930"],"is_preprint":false},{"year":2014,"finding":"The high frequency of HLA-A*0201-MART-1(26-35)-specific CD8+ T cells is explained by two independent mechanisms: (1) biased TRAV12-2 (Vα) usage, where combinatorial pairing of different TCRα and TCRβ chains confers MART-1 specificity provided CDR1α TRAV12-2 is used; and (2) misinitiated truncated MART-1 transcripts in medullary thymic epithelial cells that lack the MART-1(26-35) epitope, enabling evasion of central self-tolerance.","method":"TCR chain combinatorial pairing experiments in cell lines, RT-PCR analysis of MART-1 transcripts in thymic epithelial cells, HLA-A2-MART-1 tetramer staining","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional TCR reconstitution combined with molecular characterization of thymic transcripts; two orthogonal mechanistic explanations tested in a single study","pmids":["24846220"],"is_preprint":false},{"year":2011,"finding":"Two MART-1-specific TCRs used in cancer gene therapy (DMF4 and DMF5) cross-react with two structurally distinct MART-1/Melan-A peptide epitopes via distinct mechanisms: DMF4 binds the two peptides with different orientations over the peptide/MHC surface, while DMF5 binds both identically; DMF5's simpler cross-reactivity mode is associated with higher affinity for both ligands.","method":"X-ray crystallography of TCR/peptide-MHC complexes (structures of DMF4 and DMF5 with both MART-1 epitopes), functional avidity measurements","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystallographic structures with functional affinity validation; multiple structures solved in single study providing mechanistic insight into TCR cross-reactivity","pmids":["21795600"],"is_preprint":false},{"year":1998,"finding":"HLA-B45.1-restricted CTL from melanoma patients recognize MART-1 epitopes derived from residues 24-34 (11-mer AEEAAGIGILT) and 24-33 (10-mer AEEAAGIGIL), overlapping with the HLA-A2.1-restricted MART-1 epitope region; C-terminal threonine-34 is part of the CTL7/147 epitope but not required for HLA-B45.1 binding.","method":"Transfection of 3'-deletion mutants of MART-1 cDNA, synthetic peptide fine-specificity assays, cytolysis assays with CTL clones","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — deletion mutagenesis combined with peptide fine-specificity analysis; single lab with multiple orthogonal approaches","pmids":["9455808"],"is_preprint":false}],"current_model":"MART-1 (MLANA) is a melanocyte/melanoma-specific protein (~18-22 kDa) that localizes predominantly to the trans-Golgi network and premelanosomes, where it forms a physical complex with Pmel17/GP100 and OA1 (GPR143) to regulate melanosome biogenesis and maturation; its transcription is driven by the MITF transcription factor, it undergoes post-translational acylation and rapid turnover, and its best-characterized molecular function is as an escort/chaperone required for Pmel17 processing, stability, and trafficking — with MART-1 knockout mice showing coat color dilution and stage III/IV melanosome morphological defects; additionally, MART-1 encodes highly immunodominant HLA-A*0201-restricted (AAGIGILTV/EAAGIGILTV) and HLA-DR4-restricted (residues 51-73) T-cell epitopes that are naturally processed and presented on melanoma cell surfaces."},"narrative":{"mechanistic_narrative":"MLANA (MART-1/Melan-A) is a melanocyte-specific protein that functions in melanosome biogenesis and maturation [PMID:15695812, PMID:21943097]. It is post-translationally acylated, undergoes rapid turnover, and concentrates in the trans-Golgi network and on small vesicles, with substantial labeling on premelanosome limiting membranes that redistributes to internal membranes as melanosomes mature — a distribution distinct from typical melanosomal cargo and consistent with a role in early melanosome biogenesis [PMID:12191019]. Mechanistically, MART-1 acts as an escort/stabilizing partner: it forms a physical complex with Pmel17/GP100 and is required for Pmel17 expression, stability, trafficking, and proteolytic processing, with knockdown impairing and re-expression rescuing Pmel17 function [PMID:15695812], and it likewise interacts with the intracellular GPCR OA1/GPR143 to maintain OA1 stability and proper premelanosome composition [PMID:19717472]. In vivo, MART-1 knockout mice show coat-color dilution, reduced melanin, and stage III/IV melanosome morphological defects, confirming a requirement in late-stage melanosome biogenesis [PMID:21943097]. MLANA transcription is driven by MITF, which binds conserved consensus elements in the MLANA promoter/enhancer [PMID:12819038]. Independently of its melanosomal role, MART-1 is a major melanoma tumor antigen: it encodes immunodominant HLA-A*0201-restricted epitopes (the AAGIGILTV nonamer and the optimal EAAGIGILTV decamer) that are naturally processed and presented on melanoma cell surfaces [PMID:7516411, PMID:9278327, PMID:10417764], plus an HLA-DR4-restricted CD4+ T-cell epitope [PMID:10618430], and the anti-MART-1 CTL response shows characteristically biased TCR usage [PMID:7777568, PMID:24846220].","teleology":[{"year":1994,"claim":"Established MART-1 as a bona fide melanoma rejection antigen by defining the HLA-A2-restricted CTL epitope recognized by most melanoma-specific tumor-infiltrating lymphocytes, answering what tumor target dominant anti-melanoma T cells see.","evidence":"Peptide synthesis from HLA-A2.1 motifs, T2 pulsing, and cytolysis assays with TIL from 10 patients","pmids":["7516411"],"confidence":"High","gaps":["Did not establish the protein's normal cellular function","Optimal epitope length not yet defined"]},{"year":1996,"claim":"Biochemically characterized the MART-1 protein as a ~18-22 kDa cytoplasmic/melanosomal/ER protein lacking detectable melanogenic enzymatic activity, framing it as a non-enzymatic melanosomal protein of unknown function.","evidence":"Recombinant protein, monoclonal antibodies, IP, Western blot, immunocytochemistry, and subcellular fractionation","pmids":["8650193","9075767"],"confidence":"Medium","gaps":["Molecular function unresolved","Doublet/size discrepancy not explained at the time"]},{"year":1996,"claim":"Broadened the antigenic relevance of the MART-1(27-35) epitope by showing presentation across multiple HLA-A2 subtypes and an additional HLA-B45.1-restricted epitope cluster, defining the breadth of MHC restriction.","evidence":"Peptide pulsing of B-LCLs expressing defined HLA alleles, 3' deletion mutagenesis, and cytolysis assays","pmids":["8752930","9455808"],"confidence":"Medium","gaps":["Single-lab allele panels","Natural processing for B45.1 epitopes not confirmed by mass spectrometry"]},{"year":1997,"claim":"Refined the immunodominant epitope to the optimal EAAGIGILTV decamer, clarifying which peptide form drives the dominant CTL response and improving vaccine/diagnostic design.","evidence":"Quantitative functional CTL assays with polyclonal/monoclonal populations and HLA-A2 binding assays","pmids":["9278327"],"confidence":"High","gaps":["Did not address endogenous processing pathway"]},{"year":1999,"claim":"Confirmed that the AAGIGILTV epitope is genuinely processed and surface-presented on melanoma cells, closing the gap between synthetic-peptide recognition and endogenous antigen presentation.","evidence":"Direct isolation of HLA-A*0201-bound peptides from melanoma cells and mass-spectrometric identification","pmids":["10417764"],"confidence":"High","gaps":["Quantitative density of the epitope per cell not established"]},{"year":2000,"claim":"Extended antigen recognition to the CD4+ compartment by defining an HLA-DR4-restricted MART-1 epitope, indicating helper T-cell engagement against the antigen.","evidence":"CD4+ T-cell expansion with peptide-pulsed dendritic cells, IFN-γ production, and cytolysis assays","pmids":["10618430"],"confidence":"Medium","gaps":["Single-lab functional readout","Natural processing of the DR4 epitope not directly demonstrated"]},{"year":2002,"claim":"Mapped MART-1's precise subcellular itinerary and acylation, showing a TGN/vesicle-concentrated distribution distinct from typical melanosomal proteins and pointing to a role in early melanosome biogenesis rather than pigment synthesis.","evidence":"Biochemical acylation analysis, immunofluorescence, and quantitative immunoelectron microscopy","pmids":["12191019"],"confidence":"High","gaps":["Did not identify molecular binding partners","Functional consequence of acylation not tested"]},{"year":2003,"claim":"Identified MITF as the transcription factor driving MLANA expression, placing the gene within the melanocyte master-regulator transcriptional network.","evidence":"EMSA, ChIP, promoter/reporter assays, and MITF up/down-modulation in melanoma cells","pmids":["12819038"],"confidence":"High","gaps":["Other co-regulators of the MLANA promoter not defined"]},{"year":2005,"claim":"Defined MART-1's first molecular function: a physical partner and chaperone required for Pmel17/GP100 stability, trafficking, and proteolytic processing, explaining how it contributes to melanosome structure.","evidence":"siRNA knockdown, transfection rescue, co-IP, Western blot, and electron microscopy","pmids":["15695812"],"confidence":"High","gaps":["Direct binding interface not mapped","Whether the effect is direct chaperoning vs. trafficking facilitation unresolved"]},{"year":2009,"claim":"Generalized the escort function by showing MART-1 stabilizes the intracellular GPCR OA1/GPR143, indicating it supports multiple premelanosomal clients during early melanogenesis.","evidence":"siRNA knockdown of MART-1 and OA1, co-IP, immunofluorescence, and EM of melanosome ultrastructure","pmids":["19717472"],"confidence":"High","gaps":["Structural basis of MART-1/OA1 interaction unknown","Relationship between OA1 and Pmel17 escort roles not integrated"]},{"year":2011,"claim":"Provided in vivo validation of MART-1's melanosomal role, showing knockout causes coat-color dilution and selective stage III/IV melanosome defects without disrupting other melanocyte proteins.","evidence":"Knockout mouse model, coat-color phenotyping, melanosome EM, and immunofluorescence","pmids":["21943097"],"confidence":"High","gaps":["In this model Pmel17 maturation appeared unaffected, leaving the stage of action partly unresolved relative to cell-line data"]},{"year":2014,"claim":"Explained the unusually high precursor frequency of MART-1-specific CD8+ T cells through biased TRAV12-2 usage and thymic escape via misinitiated epitope-lacking transcripts, clarifying the immunobiology of the dominant response.","evidence":"TCR combinatorial pairing in cell lines, RT-PCR of thymic MART-1 transcripts, and tetramer staining","pmids":["24846220","7777568","21795600"],"confidence":"Medium","gaps":["Thymic transcript escape mechanism not validated in vivo in humans","Relative contribution of the two mechanisms not quantified"]},{"year":null,"claim":"How MART-1 mechanistically chaperones its clients (direct binding interface, role of acylation, and reconciliation of the early- vs late-stage melanosome requirement) remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No structural model of MART-1 or its complexes with Pmel17/OA1","Functional role of acylation untested by mutagenesis","Identity of the secreted factor that silences MLANA transcription unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0044183","term_label":"protein folding chaperone","supporting_discovery_ids":[5,6]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[5]}],"localization":[{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[4]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[4]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[2,3,4]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[5,6,8]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,9,10]}],"complexes":[],"partners":["PMEL","GPR143","MITF"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q16655","full_name":"Melanoma antigen recognized by T-cells 1","aliases":["Antigen LB39-AA","Antigen SK29-AA","Protein Melan-A"],"length_aa":118,"mass_kda":13.2,"function":"Involved in melanosome biogenesis by ensuring the stability of GPR143. Plays a vital role in the expression, stability, trafficking, and processing of melanocyte protein PMEL, which is critical to the formation of stage II melanosomes","subcellular_location":"Endoplasmic reticulum membrane; Golgi apparatus; Golgi apparatus, trans-Golgi network membrane; Melanosome","url":"https://www.uniprot.org/uniprotkb/Q16655/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MLANA","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MLANA","total_profiled":1310},"omim":[{"mim_id":"605743","title":"HEDGEHOG ACYLTRANSFERASE; HHAT","url":"https://www.omim.org/entry/605743"},{"mim_id":"605513","title":"MELAN A; MLANA","url":"https://www.omim.org/entry/605513"},{"mim_id":"300808","title":"G PROTEIN-COUPLED RECEPTOR 143; GPR143","url":"https://www.omim.org/entry/300808"},{"mim_id":"155550","title":"PREMELANOSOME PROTEIN; PMEL","url":"https://www.omim.org/entry/155550"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"skin 1","ntpm":40.6}],"url":"https://www.proteinatlas.org/search/MLANA"},"hgnc":{"alias_symbol":["MART1","MART-1"],"prev_symbol":[]},"alphafold":{"accession":"Q16655","domains":[{"cath_id":"1.20.5","chopping":"24-51","consensus_level":"high","plddt":88.3671,"start":24,"end":51}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16655","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q16655-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q16655-F1-predicted_aligned_error_v6.png","plddt_mean":63.91},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MLANA","jax_strain_url":"https://www.jax.org/strain/search?query=MLANA"},"sequence":{"accession":"Q16655","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16655.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16655/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16655"}},"corpus_meta":[{"pmid":"7516411","id":"PMC_7516411","title":"Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.","date":"1994","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7516411","citation_count":761,"is_preprint":false},{"pmid":"9469433","id":"PMC_9469433","title":"Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9469433","citation_count":381,"is_preprint":false},{"pmid":"7868898","id":"PMC_7868898","title":"Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7868898","citation_count":278,"is_preprint":false},{"pmid":"9072306","id":"PMC_9072306","title":"Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.","date":"1997","source":"The cancer journal from Scientific American","url":"https://pubmed.ncbi.nlm.nih.gov/9072306","citation_count":268,"is_preprint":false},{"pmid":"12819038","id":"PMC_12819038","title":"MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma.","date":"2003","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12819038","citation_count":233,"is_preprint":false},{"pmid":"8833913","id":"PMC_8833913","title":"Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.","date":"1996","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/8833913","citation_count":227,"is_preprint":false},{"pmid":"24634374","id":"PMC_24634374","title":"Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/24634374","citation_count":201,"is_preprint":false},{"pmid":"16971810","id":"PMC_16971810","title":"Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.","date":"2006","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/16971810","citation_count":182,"is_preprint":false},{"pmid":"8650193","id":"PMC_8650193","title":"Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8650193","citation_count":177,"is_preprint":false},{"pmid":"9230191","id":"PMC_9230191","title":"Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells.","date":"1997","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9230191","citation_count":162,"is_preprint":false},{"pmid":"9422316","id":"PMC_9422316","title":"Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors.","date":"1998","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9422316","citation_count":160,"is_preprint":false},{"pmid":"9242453","id":"PMC_9242453","title":"Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.","date":"1997","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9242453","citation_count":158,"is_preprint":false},{"pmid":"8760818","id":"PMC_8760818","title":"Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).","date":"1996","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8760818","citation_count":149,"is_preprint":false},{"pmid":"15695812","id":"PMC_15695812","title":"MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanosomes.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15695812","citation_count":147,"is_preprint":false},{"pmid":"8811494","id":"PMC_8811494","title":"Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.","date":"1996","source":"Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/8811494","citation_count":126,"is_preprint":false},{"pmid":"21795600","id":"PMC_21795600","title":"TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21795600","citation_count":126,"is_preprint":false},{"pmid":"9820539","id":"PMC_9820539","title":"Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9820539","citation_count":125,"is_preprint":false},{"pmid":"9278327","id":"PMC_9278327","title":"Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9278327","citation_count":125,"is_preprint":false},{"pmid":"10618430","id":"PMC_10618430","title":"Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10618430","citation_count":124,"is_preprint":false},{"pmid":"12445283","id":"PMC_12445283","title":"Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.","date":"2002","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12445283","citation_count":122,"is_preprint":false},{"pmid":"9407964","id":"PMC_9407964","title":"Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors.","date":"1997","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9407964","citation_count":108,"is_preprint":false},{"pmid":"7777568","id":"PMC_7777568","title":"Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7777568","citation_count":104,"is_preprint":false},{"pmid":"16651452","id":"PMC_16651452","title":"Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16651452","citation_count":101,"is_preprint":false},{"pmid":"15294960","id":"PMC_15294960","title":"Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15294960","citation_count":96,"is_preprint":false},{"pmid":"8671669","id":"PMC_8671669","title":"Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease.","date":"1996","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8671669","citation_count":95,"is_preprint":false},{"pmid":"25896248","id":"PMC_25896248","title":"Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor.","date":"2015","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25896248","citation_count":91,"is_preprint":false},{"pmid":"18317358","id":"PMC_18317358","title":"Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.","date":"2008","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/18317358","citation_count":90,"is_preprint":false},{"pmid":"27158886","id":"PMC_27158886","title":"Mohs Micrographic Surgery Using MART-1 Immunostain in the Treatment of Invasive Melanoma and Melanoma In Situ.","date":"2016","source":"Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/27158886","citation_count":90,"is_preprint":false},{"pmid":"9075767","id":"PMC_9075767","title":"Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1.","date":"1997","source":"Journal of immunological methods","url":"https://pubmed.ncbi.nlm.nih.gov/9075767","citation_count":88,"is_preprint":false},{"pmid":"9456433","id":"PMC_9456433","title":"Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.","date":"1998","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/9456433","citation_count":87,"is_preprint":false},{"pmid":"7531614","id":"PMC_7531614","title":"Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen.","date":"1995","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7531614","citation_count":86,"is_preprint":false},{"pmid":"12925214","id":"PMC_12925214","title":"Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.","date":"2003","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/12925214","citation_count":85,"is_preprint":false},{"pmid":"16847203","id":"PMC_16847203","title":"Melanocytes in long-standing sun-exposed skin: quantitative analysis using the MART-1 immunostain.","date":"2006","source":"Archives of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/16847203","citation_count":84,"is_preprint":false},{"pmid":"11169510","id":"PMC_11169510","title":"Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.","date":"2001","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11169510","citation_count":83,"is_preprint":false},{"pmid":"7814882","id":"PMC_7814882","title":"Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7814882","citation_count":83,"is_preprint":false},{"pmid":"19949105","id":"PMC_19949105","title":"MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19949105","citation_count":80,"is_preprint":false},{"pmid":"10417764","id":"PMC_10417764","title":"Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.","date":"1999","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10417764","citation_count":80,"is_preprint":false},{"pmid":"10360670","id":"PMC_10360670","title":"Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR.","date":"1999","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10360670","citation_count":77,"is_preprint":false},{"pmid":"19717472","id":"PMC_19717472","title":"The ocular albinism type 1 (OA1) G-protein-coupled receptor functions with MART-1 at early stages of melanogenesis to control melanosome identity and composition.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19717472","citation_count":76,"is_preprint":false},{"pmid":"9820172","id":"PMC_9820172","title":"High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma.","date":"1998","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9820172","citation_count":76,"is_preprint":false},{"pmid":"9220317","id":"PMC_9220317","title":"Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.","date":"1997","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/9220317","citation_count":73,"is_preprint":false},{"pmid":"24726012","id":"PMC_24726012","title":"MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial.","date":"2014","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24726012","citation_count":71,"is_preprint":false},{"pmid":"8621927","id":"PMC_8621927","title":"Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8621927","citation_count":71,"is_preprint":false},{"pmid":"9850054","id":"PMC_9850054","title":"Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene.","date":"1998","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9850054","citation_count":71,"is_preprint":false},{"pmid":"14991540","id":"PMC_14991540","title":"HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma.","date":"2004","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/14991540","citation_count":70,"is_preprint":false},{"pmid":"10561323","id":"PMC_10561323","title":"MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases.","date":"1999","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/10561323","citation_count":70,"is_preprint":false},{"pmid":"9862732","id":"PMC_9862732","title":"HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9862732","citation_count":69,"is_preprint":false},{"pmid":"9720495","id":"PMC_9720495","title":"Comparison of melanoma antigen recognized by T cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor.","date":"1998","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/9720495","citation_count":68,"is_preprint":false},{"pmid":"9131386","id":"PMC_9131386","title":"Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy.","date":"1997","source":"International reviews of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9131386","citation_count":67,"is_preprint":false},{"pmid":"7522957","id":"PMC_7522957","title":"Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope.","date":"1994","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7522957","citation_count":67,"is_preprint":false},{"pmid":"12191019","id":"PMC_12191019","title":"The melanocytic protein Melan-A/MART-1 has a subcellular localization distinct from typical melanosomal proteins.","date":"2002","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/12191019","citation_count":66,"is_preprint":false},{"pmid":"11745443","id":"PMC_11745443","title":"Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1.","date":"2001","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11745443","citation_count":65,"is_preprint":false},{"pmid":"9764809","id":"PMC_9764809","title":"Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution.","date":"1998","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/9764809","citation_count":64,"is_preprint":false},{"pmid":"11474288","id":"PMC_11474288","title":"Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma: higher diagnostic accuracy with Melan-A and MART-1 compared with S-100 protein and HMB-45.","date":"2001","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11474288","citation_count":64,"is_preprint":false},{"pmid":"16489078","id":"PMC_16489078","title":"Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma.","date":"2006","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/16489078","citation_count":62,"is_preprint":false},{"pmid":"19554023","id":"PMC_19554023","title":"Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones.","date":"2009","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/19554023","citation_count":62,"is_preprint":false},{"pmid":"10096358","id":"PMC_10096358","title":"Melanoma-associated antigen recognized by T cells (MART-1): the advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration.","date":"1999","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10096358","citation_count":60,"is_preprint":false},{"pmid":"9378560","id":"PMC_9378560","title":"Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine.","date":"1997","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9378560","citation_count":59,"is_preprint":false},{"pmid":"18481391","id":"PMC_18481391","title":"Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.","date":"2008","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/18481391","citation_count":57,"is_preprint":false},{"pmid":"10383696","id":"PMC_10383696","title":"Melan-A/Mart-1 expression in various melanocytic lesions and in non-melanocytic soft tissue tumours.","date":"1999","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/10383696","citation_count":55,"is_preprint":false},{"pmid":"7591302","id":"PMC_7591302","title":"Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.","date":"1995","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/7591302","citation_count":52,"is_preprint":false},{"pmid":"10687138","id":"PMC_10687138","title":"Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells.","date":"2000","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/10687138","citation_count":51,"is_preprint":false},{"pmid":"9101414","id":"PMC_9101414","title":"Immunocytochemical detection of MART-1 in fresh and paraffin-embedded malignant melanomas.","date":"1997","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/9101414","citation_count":51,"is_preprint":false},{"pmid":"9100543","id":"PMC_9100543","title":"Effusion cytology of malignant melanoma. A morphologic and immunocytochemical analysis including application of the MART-1 antibody.","date":"1997","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9100543","citation_count":51,"is_preprint":false},{"pmid":"22495394","id":"PMC_22495394","title":"Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma.","date":"2012","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/22495394","citation_count":51,"is_preprint":false},{"pmid":"8900375","id":"PMC_8900375","title":"Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma.","date":"1996","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8900375","citation_count":48,"is_preprint":false},{"pmid":"11920589","id":"PMC_11920589","title":"Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.","date":"2002","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11920589","citation_count":48,"is_preprint":false},{"pmid":"11466335","id":"PMC_11466335","title":"A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11466335","citation_count":48,"is_preprint":false},{"pmid":"11467477","id":"PMC_11467477","title":"Expression of S100a, vimentin, NSE, and melan A/MART-1 in seven canine melanoma cells lines and twenty-nine retrospective cases of canine melanoma.","date":"2001","source":"Veterinary pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11467477","citation_count":48,"is_preprint":false},{"pmid":"17699571","id":"PMC_17699571","title":"ORF73-null murine gammaherpesvirus 68 reveals roles for mLANA and p53 in virus replication.","date":"2007","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/17699571","citation_count":46,"is_preprint":false},{"pmid":"10389626","id":"PMC_10389626","title":"Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas. An immunohistochemical and rt-PCR analysis.","date":"1999","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10389626","citation_count":46,"is_preprint":false},{"pmid":"9455808","id":"PMC_9455808","title":"Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.","date":"1998","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9455808","citation_count":46,"is_preprint":false},{"pmid":"9409451","id":"PMC_9409451","title":"Differential expression of MART-1 in primary and metastatic melanoma lesions.","date":"1997","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/9409451","citation_count":45,"is_preprint":false},{"pmid":"9862730","id":"PMC_9862730","title":"Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9862730","citation_count":45,"is_preprint":false},{"pmid":"22768350","id":"PMC_22768350","title":"Human macrophages and dendritic cells can equally present MART-1 antigen to CD8(+) T cells after phagocytosis of gamma-irradiated melanoma cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22768350","citation_count":44,"is_preprint":false},{"pmid":"17448240","id":"PMC_17448240","title":"Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes.","date":"2007","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17448240","citation_count":43,"is_preprint":false},{"pmid":"17082590","id":"PMC_17082590","title":"Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17082590","citation_count":42,"is_preprint":false},{"pmid":"8752930","id":"PMC_8752930","title":"Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8752930","citation_count":42,"is_preprint":false},{"pmid":"16353138","id":"PMC_16353138","title":"Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients.","date":"2006","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16353138","citation_count":41,"is_preprint":false},{"pmid":"11698460","id":"PMC_11698460","title":"A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11698460","citation_count":40,"is_preprint":false},{"pmid":"9670966","id":"PMC_9670966","title":"Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9670966","citation_count":39,"is_preprint":false},{"pmid":"24846220","id":"PMC_24846220","title":"Misinitiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T cells.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24846220","citation_count":38,"is_preprint":false},{"pmid":"16000957","id":"PMC_16000957","title":"Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse.","date":"2005","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/16000957","citation_count":38,"is_preprint":false},{"pmid":"12645955","id":"PMC_12645955","title":"Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12645955","citation_count":37,"is_preprint":false},{"pmid":"16327495","id":"PMC_16327495","title":"Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen.","date":"2005","source":"Annals of surgery","url":"https://pubmed.ncbi.nlm.nih.gov/16327495","citation_count":37,"is_preprint":false},{"pmid":"18249038","id":"PMC_18249038","title":"Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35.","date":"2008","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/18249038","citation_count":36,"is_preprint":false},{"pmid":"14984584","id":"PMC_14984584","title":"HMB-45 (gp103) and MART-1 expression within giant cells in an atypical fibroxanthoma: a case report.","date":"2004","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/14984584","citation_count":34,"is_preprint":false},{"pmid":"12056962","id":"PMC_12056962","title":"Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma.","date":"2002","source":"Archives of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/12056962","citation_count":31,"is_preprint":false},{"pmid":"12244204","id":"PMC_12244204","title":"Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12244204","citation_count":31,"is_preprint":false},{"pmid":"12209980","id":"PMC_12209980","title":"Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen.","date":"2002","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12209980","citation_count":31,"is_preprint":false},{"pmid":"12000867","id":"PMC_12000867","title":"Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.","date":"2002","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/12000867","citation_count":30,"is_preprint":false},{"pmid":"12670905","id":"PMC_12670905","title":"Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12670905","citation_count":30,"is_preprint":false},{"pmid":"10940901","id":"PMC_10940901","title":"Synthetic insertion signal sequences enhance MHC class I presentation of a peptide from the melanoma antigen MART-1.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10940901","citation_count":29,"is_preprint":false},{"pmid":"35865122","id":"PMC_35865122","title":"MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.","date":"2022","source":"Immuno-oncology technology","url":"https://pubmed.ncbi.nlm.nih.gov/35865122","citation_count":28,"is_preprint":false},{"pmid":"16148409","id":"PMC_16148409","title":"Differential expression of MART-1, tyrosinase, and SM5-1 in primary and metastatic melanoma.","date":"2005","source":"The American Journal of dermatopathology","url":"https://pubmed.ncbi.nlm.nih.gov/16148409","citation_count":28,"is_preprint":false},{"pmid":"25043574","id":"PMC_25043574","title":"The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo.","date":"2014","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/25043574","citation_count":28,"is_preprint":false},{"pmid":"19638595","id":"PMC_19638595","title":"Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19638595","citation_count":28,"is_preprint":false},{"pmid":"21943097","id":"PMC_21943097","title":"Coat color dilution in mice because of inactivation of the melanoma antigen MART-1.","date":"2011","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/21943097","citation_count":28,"is_preprint":false},{"pmid":"15501517","id":"PMC_15501517","title":"Computational peptide dissection of Melan-a/MART-1 oncoprotein antigenicity.","date":"2004","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/15501517","citation_count":28,"is_preprint":false},{"pmid":"20628878","id":"PMC_20628878","title":"Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion.","date":"2010","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/20628878","citation_count":27,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":57313,"output_tokens":4627,"usd":0.120672,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12678,"output_tokens":3824,"usd":0.079495,"stage2_stop_reason":"end_turn"},"total_usd":0.200167,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"The MART-1 protein contains an immunodominant HLA-A2-restricted CTL epitope corresponding to the 9-mer peptide AAGIGILTV (residues 27-35), which is recognized by the majority of HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes.\",\n      \"method\": \"Peptide synthesis based on HLA-A2.1 binding motifs, T2 cell pulsing, cytolysis assays with TIL from 10 patients\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct peptide-MHC binding and functional CTL lysis assay, replicated across 10 patients and subsequently confirmed by mass spectrometry (PMID:10417764) and multiple independent labs\",\n      \"pmids\": [\"7516411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The decapeptide EAAGIGILTV (residues 26-35) is the optimal-length immunodominant MART-1 peptide for HLA-A*0201 presentation; it binds HLA-A2 more efficiently than the nonapeptide AAGIGILTV (residues 27-35) and is recognized at lower concentrations by the majority of Melan-A-specific CTL clones.\",\n      \"method\": \"Quantitative functional CTL assays (4 polyclonal and 13 monoclonal CTL populations), peptide-HLA-A2 binding assays, TCR repertoire analysis\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct binding assays combined with functional CTL recognition, multiple clones tested, findings consistent with independent replication\",\n      \"pmids\": [\"9278327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"MART-1 protein is approximately 20-22 kDa (detected as a doublet by SDS-PAGE) and localizes to the cytoplasm of melanocytes and melanoma cells; subcellular fractionation placed MART-1 in melanosomes and endoplasmic reticulum, and no known melanogenic enzymatic activities were detected in MART-1.\",\n      \"method\": \"Recombinant protein production, monoclonal antibody generation, immunoprecipitation, Western blotting, immunocytochemistry, subcellular fractionation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal biochemical methods (western, IP, fractionation, ICC) in a single study; subcellular localization confirmed but functional consequence of fractionation result not fully established\",\n      \"pmids\": [\"8650193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"MART-1 protein size is approximately 18 kDa by SDS-PAGE, suggesting possible post-translational modifications; the protein localizes to melanosomes and endoplasmic reticulum by subcellular fractionation, and no melanogenic enzymatic activities were detected.\",\n      \"method\": \"Bacterial and baculovirus recombinant expression, immunoprecipitation, Western blotting, flow cytometry, subcellular fractionation\",\n      \"journal\": \"Journal of immunological methods\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods in a single study; fractionation supports ER/melanosome localization but functional consequence not established\",\n      \"pmids\": [\"9075767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Melan-A/MART-1 is post-translationally acylated and undergoes rapid turnover; its highest concentration is in the trans-Golgi network and small vesicles/tubules throughout the cell, with substantial labeling also on melanosomes (concentrated on the limiting membrane of premelanosomes, shifting to internal vesicle membranes upon melanosome maturation), endosomes, ER, nuclear envelope, and plasma membrane — a subcellular distribution distinct from typical melanosomal proteins, suggesting a role in early melanosome biogenesis.\",\n      \"method\": \"Biochemical acylation analysis, immunofluorescence microscopy, quantitative immunoelectron microscopy\",\n      \"journal\": \"Traffic (Copenhagen, Denmark)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — quantitative immunoelectron microscopy with biochemical acylation data; multiple orthogonal methods in a single study; subcellular distribution precisely mapped\",\n      \"pmids\": [\"12191019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MART-1 forms a physical complex with Pmel17/GP100 and is required for Pmel17's expression, stability, trafficking, and proteolytic processing necessary for melanosome structure and maturation; siRNA-mediated knockdown of MART-1 in pigmented cells impairs Pmel17 function, and re-expression of MART-1 in MART-1-negative cells rescues Pmel17 processing.\",\n      \"method\": \"siRNA knockdown, transfection rescue, co-immunoprecipitation, Western blotting, electron microscopy of melanosome ultrastructure\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — co-IP demonstrates physical complex; siRNA loss-of-function and rescue experiments with defined molecular readout (Pmel17 processing/stability); multiple orthogonal methods in one study\",\n      \"pmids\": [\"15695812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MART-1 interacts biochemically with the intracellular GPCR OA1 (GPR143); siRNA inactivation of MART-1 leads to decreased OA1 stability and similar defects in premelanosome biogenesis and composition as OA1 loss, suggesting MART-1 acts as an escort protein for OA1 at early stages of melanogenesis.\",\n      \"method\": \"siRNA knockdown of MART-1 and OA1, co-immunoprecipitation, immunofluorescence, electron microscopy of melanosome ultrastructure\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — co-IP establishes physical interaction; siRNA loss-of-function with defined ultrastructural and biochemical phenotype; multiple orthogonal methods\",\n      \"pmids\": [\"19717472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MLANA/MART-1 gene expression is transcriptionally regulated by the MITF transcription factor; the MLANA promoter/enhancer contains conserved MITF consensus DNA-binding sequences that are bound by MITF in vitro and in vivo, and modulation of MITF levels correspondingly changes endogenous MLANA expression in melanoma cells.\",\n      \"method\": \"Electrophoretic mobility shift assay (EMSA), chromatin immunoprecipitation (ChIP), promoter/reporter assays, MITF up/down-regulation in melanoma cell lines\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — EMSA and ChIP both demonstrate MITF binding to MLANA regulatory sequences; reporter assays confirm functional transcriptional regulation; multiple orthogonal methods in one study\",\n      \"pmids\": [\"12819038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"MART-1 knockdown mice display coat color dilution with reduced total melanin content; MART-1 loss causes morphological abnormalities specifically in stage III and IV melanosomes of hair follicle melanocytes but does not affect localization of other melanocyte-specific proteins or maturation of Pmel17, indicating MART-1 is required for late-stage melanosome biogenesis and/or maintenance.\",\n      \"method\": \"MART-1 knockout mouse model, coat color phenotyping, electron microscopy of melanosomes, immunofluorescence for melanocyte-specific proteins\",\n      \"journal\": \"Pigment cell & melanoma research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — germline knockout with defined melanin content and ultrastructural phenotype; multiple orthogonal methods; provides in vivo validation of melanosomal function\",\n      \"pmids\": [\"21943097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"MART-1 peptide AAGIGILTV (residues 27-35) is directly identified by mass spectrometry as a naturally processed and HLA-A*0201-associated peptide isolated from the surface of human melanoma cells, confirming the endogenous processing and presentation of this CTL epitope.\",\n      \"method\": \"Peptide isolation from HLA-A*0201 molecules of melanoma cells followed by mass spectrometry identification\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct mass-spectrometric identification of naturally processed peptide from tumor cell HLA molecules; rigorous biochemical method confirming endogenous processing\",\n      \"pmids\": [\"10417764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"MART-1 encodes at least one HLA-DR4-restricted epitope (residues 51-73) recognized by CD4+ T cells; Melan-A/MART-1(51-73)-specific CD4+ T cells specifically produce IFN-γ and lyse T2.DR4 cells pulsed with the peptide and DR4+ melanoma cells naturally expressing MART-1.\",\n      \"method\": \"In vitro expansion of CD4+ T cells with peptide-pulsed autologous dendritic cells, cytokine production assay (IFN-γ), cytolysis assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional T cell recognition assay with defined peptide epitope and HLA restriction; single lab but two orthogonal functional readouts (cytokine and cytolysis)\",\n      \"pmids\": [\"10618430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Melanoma cells secrete a soluble protein factor that down-regulates MART-1/Melan-A antigen expression by acting on the MART-1 minimal promoter, leading to loss of CTL recognition; this silencing is reversible upon removal of conditioned supernatants and does not affect the HLA-A2 promoter.\",\n      \"method\": \"Promoter activity assays, conditioned media experiments, CTL recognition assay, reversal upon supernatant removal\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter assays with conditioned media plus functional CTL readout; single lab, two orthogonal methods; identity of soluble factor not determined\",\n      \"pmids\": [\"11466335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"TCR alpha chain variable region TCRAV2S1 was the predominant chain in MART-1-specific HLA-A2-restricted CTL clones (6/9 clones from 5 patients), with restricted beta-chain usage (TCRBV14 or TCRBV7), and a conserved TCRAV2S1/TCRBV14 pairing in 4 clones from 3 patients, indicating limited and conserved TCR gene usage in the anti-MART-1 CTL response.\",\n      \"method\": \"PCR with V-region gene subfamily-specific primers on cDNA from CTL clones, DNA sequencing\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct TCR sequencing from multiple patient-derived clones; single study but across 5 patients with consistent findings\",\n      \"pmids\": [\"7777568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"MART-1 peptide AAGIGILTV (27-35) is presented not only by HLA-A*0201 but also by at least six HLA-A2 variants (A*0202, A*0204, A*0205, A*0206, A*0209, and A*6901), as demonstrated by sensitization of B-LCLs expressing these alleles to lysis by MART-1(27-35)-specific CTL.\",\n      \"method\": \"Peptide pulsing of B-LCLs expressing defined HLA-A2 subtypes, cytolysis assays with MART-1-specific CTL, peptide-binding studies\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional peptide-MHC presentation demonstrated across multiple alleles; single lab but comprehensive allele panel\",\n      \"pmids\": [\"8752930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The high frequency of HLA-A*0201-MART-1(26-35)-specific CD8+ T cells is explained by two independent mechanisms: (1) biased TRAV12-2 (Vα) usage, where combinatorial pairing of different TCRα and TCRβ chains confers MART-1 specificity provided CDR1α TRAV12-2 is used; and (2) misinitiated truncated MART-1 transcripts in medullary thymic epithelial cells that lack the MART-1(26-35) epitope, enabling evasion of central self-tolerance.\",\n      \"method\": \"TCR chain combinatorial pairing experiments in cell lines, RT-PCR analysis of MART-1 transcripts in thymic epithelial cells, HLA-A2-MART-1 tetramer staining\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional TCR reconstitution combined with molecular characterization of thymic transcripts; two orthogonal mechanistic explanations tested in a single study\",\n      \"pmids\": [\"24846220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Two MART-1-specific TCRs used in cancer gene therapy (DMF4 and DMF5) cross-react with two structurally distinct MART-1/Melan-A peptide epitopes via distinct mechanisms: DMF4 binds the two peptides with different orientations over the peptide/MHC surface, while DMF5 binds both identically; DMF5's simpler cross-reactivity mode is associated with higher affinity for both ligands.\",\n      \"method\": \"X-ray crystallography of TCR/peptide-MHC complexes (structures of DMF4 and DMF5 with both MART-1 epitopes), functional avidity measurements\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystallographic structures with functional affinity validation; multiple structures solved in single study providing mechanistic insight into TCR cross-reactivity\",\n      \"pmids\": [\"21795600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"HLA-B45.1-restricted CTL from melanoma patients recognize MART-1 epitopes derived from residues 24-34 (11-mer AEEAAGIGILT) and 24-33 (10-mer AEEAAGIGIL), overlapping with the HLA-A2.1-restricted MART-1 epitope region; C-terminal threonine-34 is part of the CTL7/147 epitope but not required for HLA-B45.1 binding.\",\n      \"method\": \"Transfection of 3'-deletion mutants of MART-1 cDNA, synthetic peptide fine-specificity assays, cytolysis assays with CTL clones\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — deletion mutagenesis combined with peptide fine-specificity analysis; single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"9455808\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MART-1 (MLANA) is a melanocyte/melanoma-specific protein (~18-22 kDa) that localizes predominantly to the trans-Golgi network and premelanosomes, where it forms a physical complex with Pmel17/GP100 and OA1 (GPR143) to regulate melanosome biogenesis and maturation; its transcription is driven by the MITF transcription factor, it undergoes post-translational acylation and rapid turnover, and its best-characterized molecular function is as an escort/chaperone required for Pmel17 processing, stability, and trafficking — with MART-1 knockout mice showing coat color dilution and stage III/IV melanosome morphological defects; additionally, MART-1 encodes highly immunodominant HLA-A*0201-restricted (AAGIGILTV/EAAGIGILTV) and HLA-DR4-restricted (residues 51-73) T-cell epitopes that are naturally processed and presented on melanoma cell surfaces.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MLANA (MART-1/Melan-A) is a melanocyte-specific protein that functions in melanosome biogenesis and maturation [#5, #8]. It is post-translationally acylated, undergoes rapid turnover, and concentrates in the trans-Golgi network and on small vesicles, with substantial labeling on premelanosome limiting membranes that redistributes to internal membranes as melanosomes mature \\u2014 a distribution distinct from typical melanosomal cargo and consistent with a role in early melanosome biogenesis [#4]. Mechanistically, MART-1 acts as an escort/stabilizing partner: it forms a physical complex with Pmel17/GP100 and is required for Pmel17 expression, stability, trafficking, and proteolytic processing, with knockdown impairing and re-expression rescuing Pmel17 function [#5], and it likewise interacts with the intracellular GPCR OA1/GPR143 to maintain OA1 stability and proper premelanosome composition [#6]. In vivo, MART-1 knockout mice show coat-color dilution, reduced melanin, and stage III/IV melanosome morphological defects, confirming a requirement in late-stage melanosome biogenesis [#8]. MLANA transcription is driven by MITF, which binds conserved consensus elements in the MLANA promoter/enhancer [#7]. Independently of its melanosomal role, MART-1 is a major melanoma tumor antigen: it encodes immunodominant HLA-A*0201-restricted epitopes (the AAGIGILTV nonamer and the optimal EAAGIGILTV decamer) that are naturally processed and presented on melanoma cell surfaces [#0, #1, #9], plus an HLA-DR4-restricted CD4+ T-cell epitope [#10], and the anti-MART-1 CTL response shows characteristically biased TCR usage [#12, #14].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established MART-1 as a bona fide melanoma rejection antigen by defining the HLA-A2-restricted CTL epitope recognized by most melanoma-specific tumor-infiltrating lymphocytes, answering what tumor target dominant anti-melanoma T cells see.\",\n      \"evidence\": \"Peptide synthesis from HLA-A2.1 motifs, T2 pulsing, and cytolysis assays with TIL from 10 patients\",\n      \"pmids\": [\"7516411\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the protein's normal cellular function\", \"Optimal epitope length not yet defined\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Biochemically characterized the MART-1 protein as a ~18-22 kDa cytoplasmic/melanosomal/ER protein lacking detectable melanogenic enzymatic activity, framing it as a non-enzymatic melanosomal protein of unknown function.\",\n      \"evidence\": \"Recombinant protein, monoclonal antibodies, IP, Western blot, immunocytochemistry, and subcellular fractionation\",\n      \"pmids\": [\"8650193\", \"9075767\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular function unresolved\", \"Doublet/size discrepancy not explained at the time\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Broadened the antigenic relevance of the MART-1(27-35) epitope by showing presentation across multiple HLA-A2 subtypes and an additional HLA-B45.1-restricted epitope cluster, defining the breadth of MHC restriction.\",\n      \"evidence\": \"Peptide pulsing of B-LCLs expressing defined HLA alleles, 3' deletion mutagenesis, and cytolysis assays\",\n      \"pmids\": [\"8752930\", \"9455808\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab allele panels\", \"Natural processing for B45.1 epitopes not confirmed by mass spectrometry\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Refined the immunodominant epitope to the optimal EAAGIGILTV decamer, clarifying which peptide form drives the dominant CTL response and improving vaccine/diagnostic design.\",\n      \"evidence\": \"Quantitative functional CTL assays with polyclonal/monoclonal populations and HLA-A2 binding assays\",\n      \"pmids\": [\"9278327\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address endogenous processing pathway\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Confirmed that the AAGIGILTV epitope is genuinely processed and surface-presented on melanoma cells, closing the gap between synthetic-peptide recognition and endogenous antigen presentation.\",\n      \"evidence\": \"Direct isolation of HLA-A*0201-bound peptides from melanoma cells and mass-spectrometric identification\",\n      \"pmids\": [\"10417764\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative density of the epitope per cell not established\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Extended antigen recognition to the CD4+ compartment by defining an HLA-DR4-restricted MART-1 epitope, indicating helper T-cell engagement against the antigen.\",\n      \"evidence\": \"CD4+ T-cell expansion with peptide-pulsed dendritic cells, IFN-\\u03b3 production, and cytolysis assays\",\n      \"pmids\": [\"10618430\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab functional readout\", \"Natural processing of the DR4 epitope not directly demonstrated\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Mapped MART-1's precise subcellular itinerary and acylation, showing a TGN/vesicle-concentrated distribution distinct from typical melanosomal proteins and pointing to a role in early melanosome biogenesis rather than pigment synthesis.\",\n      \"evidence\": \"Biochemical acylation analysis, immunofluorescence, and quantitative immunoelectron microscopy\",\n      \"pmids\": [\"12191019\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify molecular binding partners\", \"Functional consequence of acylation not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified MITF as the transcription factor driving MLANA expression, placing the gene within the melanocyte master-regulator transcriptional network.\",\n      \"evidence\": \"EMSA, ChIP, promoter/reporter assays, and MITF up/down-modulation in melanoma cells\",\n      \"pmids\": [\"12819038\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other co-regulators of the MLANA promoter not defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined MART-1's first molecular function: a physical partner and chaperone required for Pmel17/GP100 stability, trafficking, and proteolytic processing, explaining how it contributes to melanosome structure.\",\n      \"evidence\": \"siRNA knockdown, transfection rescue, co-IP, Western blot, and electron microscopy\",\n      \"pmids\": [\"15695812\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding interface not mapped\", \"Whether the effect is direct chaperoning vs. trafficking facilitation unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Generalized the escort function by showing MART-1 stabilizes the intracellular GPCR OA1/GPR143, indicating it supports multiple premelanosomal clients during early melanogenesis.\",\n      \"evidence\": \"siRNA knockdown of MART-1 and OA1, co-IP, immunofluorescence, and EM of melanosome ultrastructure\",\n      \"pmids\": [\"19717472\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of MART-1/OA1 interaction unknown\", \"Relationship between OA1 and Pmel17 escort roles not integrated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Provided in vivo validation of MART-1's melanosomal role, showing knockout causes coat-color dilution and selective stage III/IV melanosome defects without disrupting other melanocyte proteins.\",\n      \"evidence\": \"Knockout mouse model, coat-color phenotyping, melanosome EM, and immunofluorescence\",\n      \"pmids\": [\"21943097\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In this model Pmel17 maturation appeared unaffected, leaving the stage of action partly unresolved relative to cell-line data\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Explained the unusually high precursor frequency of MART-1-specific CD8+ T cells through biased TRAV12-2 usage and thymic escape via misinitiated epitope-lacking transcripts, clarifying the immunobiology of the dominant response.\",\n      \"evidence\": \"TCR combinatorial pairing in cell lines, RT-PCR of thymic MART-1 transcripts, and tetramer staining\",\n      \"pmids\": [\"24846220\", \"7777568\", \"21795600\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Thymic transcript escape mechanism not validated in vivo in humans\", \"Relative contribution of the two mechanisms not quantified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How MART-1 mechanistically chaperones its clients (direct binding interface, role of acylation, and reconciliation of the early- vs late-stage melanosome requirement) remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model of MART-1 or its complexes with Pmel17/OA1\", \"Functional role of acylation untested by mutagenesis\", \"Identity of the secreted factor that silences MLANA transcription unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [5, 6]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [2, 3, 4]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [5, 6, 8]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 9, 10]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PMEL\", \"GPR143\", \"MITF\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}